ザイロリック錠１００ １００ｍｇ
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00437 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 100 |
| 日本商品名（例） | アロプリノール錠１００ｍｇ「あゆみ」, アロプリノール錠１００ｍｇ「アメル」, アロプリノール錠１００ｍｇ「ケミファ」 |
承認適応症（KEGG）
痛風
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | obsolete hyperuricemia (disease) | 99% | DL |
| 2 | acute urate nephropathy | 99% | DL |
| 3 | hepatic porphyria | 99% | DL |
| 4 | idiopathic copper-associated cirrhosis | 99% | DL |
| 5 | hepatoportal sclerosis | 99% | DL |
| 6 | primitive portal vein thrombosis | 99% | DL |
| 7 | hepatopulmonary syndrome | 99% | DL |
| 8 | early-onset familial noncirrhotic portal hypertension | 99% | DL |
| 9 | disorder of phenylalanine metabolism | 99% | DL |
| 10 | gout | 99% | DL |
| 11 | immune-mediated necrotizing myopathy | 99% | DL |
| 12 | antisynthetase syndrome | 99% | DL |
| 13 | idiopathic eosinophilic myositis | 99% | DL |
| 14 | inflammatory myopathy with abundant macrophages | 99% | DL |
| 15 | focal myositis | 99% | DL |
| 16 | glycogen storage disease due to hepatic glycogen synthase deficiency | 99% | DL |
| 17 | G6PD deficiency | 99% | DL |
| 18 | disorder of tyrosine metabolism | 99% | DL |
| 19 | teratogenic Pierre Robin syndrome | 99% | DL |
| 20 | selective IgG immunodeficiency | 99% | DL |
| 21 | Lesch-Nyhan syndrome | 99% | DL |
| 22 | tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria | 99% | DL |
| 23 | galactosemia | 99% | DL |
| 24 | hypouricemia, renal | 99% | DL |
| 25 | sclerosing cholangitis | 99% | DL |
| 26 | granulomatous disease, chronic, X-linked | 99% | DL |
| 27 | anemia, nonspherocytic hemolytic, due to G6PD deficiency | 99% | DL |
| 28 | selective IgG subclass deficiency | 99% | DL |
| 29 | dermatomyositis | 99% | DL |
| 30 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | 99% | DL |
| 31 | genetic otorhinolaryngological malformation | 99% | DL |
| 32 | cystinosis | 99% | DL |
| 33 | recurrent infections associated with rare immunoglobulin isotypes deficiency | 99% | DL |
| 34 | neonatal epileptic encephalopathy due to glutaminase deficiency | 99% | DL |
| 35 | galactokinase deficiency | 99% | DL |
| 36 | idiopathic bilateral vestibulopathy | 99% | DL |
| 37 | semicircular canal dehiscence syndrome | 99% | DL |
| 38 | juvenile nasopharyngeal angiofibroma (disease) | 99% | DL |
| 39 | familial nasal acilia | 99% | DL |
| 40 | silent sinus syndrome | 99% | DL |
| 41 | inborn disorder of histidine metabolism | 99% | DL |
| 42 | tetrahydrobiopterin metabolic process disease | 99% | DL |
| 43 | cerebral creatine deficiency syndrome | 99% | DL |
| 44 | inborn disorder of phenylalanin or tyrosine metabolism | 99% | DL |
| 45 | hypoxanthine guanine phosphoribosyltransferase partial deficiency | 99% | DL |
| 46 | 3-hydroxyisobutyryl-CoA hydrolase deficiency | 99% | DL |
| 47 | phenylketonuria | 99% | DL |
| 48 | paraplegia | 99% | DL |
| 49 | inborn disorder of ornithine metabolism | 99% | DL |
| 50 | renal tubular acidosis | 99% | DL |
（上位50件を表示。全100件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。